- Home
- SRRK
as 11-15-2024 4:00pm EST
Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGFβ1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 2.8B | IPO Year: | 2018 |
| Target Price: | $34.00 | AVG Volume (30 days): | 984.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.82 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.76 - $35.38 | Next Earning Date: | 11-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Scholar Rock Holding Corporation (SRRK)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Myles Edward H | SRRK | COO & CFO | Oct 8 '24 | Sell | $34.90 | 37,187 | $1,297,658.96 | 161,088 | |
| Myles Edward H | SRRK | COO & CFO | Oct 7 '24 | Sell | $27.19 | 206,240 | $5,477,545.64 | 161,088 | |
| AKKARAJU SRINIVAS | SRRK | Director | Oct 7 '24 | Sell | $30.00 | 1,175,713 | $34,385,672.50 | 5,612,896 | |
| Marantz Jing L. | SRRK | CHIEF MEDICAL OFFICER | Oct 7 '24 | Sell | $27.29 | 109,375 | $2,976,467.65 | 114,782 | |
| Sacco Tracey | SRRK | CHIEF COMMERCIAL OFFICER | Oct 7 '24 | Sell | $25.91 | 30,000 | $768,676.60 | 51,249 |
Latest Scholar Rock Holding Corporation News
SRRK Breaking Stock News: Dive into SRRK Ticker-Specific Updates for Smart Investing
Business Wire
2 days ago
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GuruFocus.com
4 days ago
Scholar Rock Holding Corp (SRRK) Q3 2024 Earnings Call Highlights: Strategic Advances and ...
MT Newswires
5 days ago
Wedbush Raises Price Target on Scholar Rock to $40 From $37, Maintains Outperform Rating
MT Newswires
5 days ago
Scholar Rock Holding Q3 Net Loss Widens
Business Wire
5 days ago
Scholar Rock Reports Third Quarter 2024 Financial Results and Highlights Business Progress
GuruFocus.com
6 days ago
Scholar Rock Holding Corp (SRRK) Q3 2024: Everything You Need To Know Ahead Of Earnings
Business Wire
13 days ago
Scholar Rock Announces New Preclinical Data for SRK-439 Showing Significant Lean Mass Increase and Enhanced Fat Mass Loss with Metformin
Business Wire
16 days ago
Scholar Rock to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024
Compare SRRK vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SRRK Scholar Rock Holding Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.